Skip to content
  • PAD
    • Pounce System
    • DETOUR System
    • DETOUR System Reimbursement
    • DETOUR Professional Education
    • For PAD Patients
    • Find a Doctor
  • AAA
    • AAA
    • ALTO
    • AFX2
    • EVAR for Women
    • EVAR Portfolio Resources
    • Clinical Evidence
    • Procedural Training
  • IFU’s
  • About Us
    • About Us
    • News
    • The Team
    • Careers
      • Internal Applicant Portal
      • External Applicant Portal
    • Investigator Initiated
      Research
    • Contact Us
  • PAD
    • Pounce System
    • DETOUR System
    • DETOUR System Reimbursement
    • DETOUR Professional Education
    • For PAD Patients
    • Find a Doctor
  • AAA
    • AAA
    • ALTO
    • AFX2
    • EVAR for Women
    • EVAR Portfolio Resources
    • Clinical Evidence
    • Procedural Training
  • IFU’s
  • About Us
    • About Us
    • News
    • The Team
    • Careers
      • Internal Applicant Portal
      • External Applicant Portal
    • Investigator Initiated
      Research
    • Contact Us
Back to News
  • January 25, 2017

Positive Three-Year Results from the Ovation® European Post Market Registry Presented at 2017 LINC Symposium

PrevPreviousEndologix Announces Reinstatement of CE Mark for AFX® and AFX®2 Endovascular AAA System
NextEndologix Announces Appointment of Dan Lemaitre as Chairman of the Board John McDermott to Continue as Chief Executive OfficerNext
FIND IFU HERE
Youtube Linkedin Twitter
Compliance
Privacy Policy
Safety Information
Anti-Trafficking/Modern Slavery
Carbon Reduction Plan UK
Cookie Policy
Terms & Conditions
Patents

© 2026 Endologix LLC. All rights reserved.

Endologix® products and associated components are not available in all countries or regions. Please contact your Endologix representative for details regarding product availability. Prior to use, refer to the “Instructions for Use” for complete and specificindications, contraindications, all warnings and precautions. Rx only.